Mikhail Blagosklonny is a scientist. He is known for his deep passion for studying aging and cancer. He currently works at the Roswell Park Cancer Institute, NY where he takes the position of an oncology professor. Mikhail is driven by his dream of slowing the process of aging and the prevention and cure of cancer. He continues to study on methods of preventing aging and cancer and the possible treatments. The research interests of Blagosklonny include cancer and the targeted cancer therapies to be used in the protection of the human’s normal cells. He also research about biogerontology. This is the underlying mechanism behind aging.
Mikhail Blagosklonny is an oncologist. He is known all over the world for his tremendous contributions in Rapamycin. This is a potential cancer treatment drug. He created a hypothesis regarding the potential TOR signaling role in both cancer and aging. Mikhail has gone into records as one of the most fervent advocates of the rapamycin drug in the research for longevity. Mikhail is involved with the peer-reviewed journal known as Oncotarget where he is the Editor-in-Chief. His experience and skills as a scientist have helped the journal to acquire readership from all parts of the world. Blagosklonny is the associate editor working for the Cancer Biology and Therapy.
Mikhail Blagosklonny is a key member of the editorial board at Cell Death and Differentiation. He has managed to publish many papers regarding oncology, cancer, and aging. His papers have more than twenty thousand citations. This has given Mikhail 83 h-index. Blagosklonny mostly deals with signal transduction, tumor suppressors, apoptosis, cellular biology, mitosis, anticancer therapeutics, and cancer cell cycling in his scientific research. He is involved with PLOS ONE, The American Journal of Pathology, and Autophagy where he is the associate editor. Mikhail is the co-founder and also the co-editor of Oncoscience. Visit ResearchGate to keep up to date with Mikhail’s latest work.
Blagosklonny has a Master’s Degree in Internal Medicine which he acquired at the First Pavlov State Medical University, St. Petersburg. He also has a Ph.D. in Experimental Medicine and Cardiology from the same University. Mikhail Blagosklonny joined the Roswell Park Cancer Institute in 2009 after working for several institutions such as the New York Medical College. View Mikhail’s profile on Google Scholar